Chronic myeloid leukemia, version 1.2019

Jerald P. Radich, Michael Deininger, Camille N. Abboud, Jessica K. Altman, Ellin Berman, Ravi Bhatia, Bhavana Bhatnagar, Peter Curtin, Daniel J. DeAngelo, Jason Gotlib, Gabriela Hobbs, Madan Jagasia, Hagop M. Kantarjian, Lori J Maness-Harris, Leland Metheny, Joseph O. Moore, Arnel Pallera, Philip Pancari, Mrinal Patnaik, Enkhtsetseg PurevMichal G. Rose, Neil P. Shah, B. Douglas Smith, David S. Snyder, Kendra L. Sweet, Moshe Talpaz, James Thompson, David T. Yang, Kristina M. Gregory, Hema Sundar

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor (TKI) therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML (CP-CML). The selection TKI therapy should be based on the risk score, toxicity profile of TKI, patient’s age, ability to tolerate therapy, and the presence of comorbid conditions. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CP-CML.

Original languageEnglish (US)
Pages (from-to)1108-1135
Number of pages28
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume16
Issue number9
DOIs
StatePublished - Sep 1 2018

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Leukemia, Myeloid, Chronic Phase
Blast Crisis
Chromosomes, Human, Pair 22
Philadelphia Chromosome
Chromosomes, Human, Pair 9
Gene Fusion
Therapeutics
Guidelines

ASJC Scopus subject areas

  • Oncology

Cite this

Radich, J. P., Deininger, M., Abboud, C. N., Altman, J. K., Berman, E., Bhatia, R., ... Sundar, H. (2018). Chronic myeloid leukemia, version 1.2019. JNCCN Journal of the National Comprehensive Cancer Network, 16(9), 1108-1135. https://doi.org/10.6004/jnccn.2018.0071

Chronic myeloid leukemia, version 1.2019. / Radich, Jerald P.; Deininger, Michael; Abboud, Camille N.; Altman, Jessica K.; Berman, Ellin; Bhatia, Ravi; Bhatnagar, Bhavana; Curtin, Peter; DeAngelo, Daniel J.; Gotlib, Jason; Hobbs, Gabriela; Jagasia, Madan; Kantarjian, Hagop M.; Maness-Harris, Lori J; Metheny, Leland; Moore, Joseph O.; Pallera, Arnel; Pancari, Philip; Patnaik, Mrinal; Purev, Enkhtsetseg; Rose, Michal G.; Shah, Neil P.; Smith, B. Douglas; Snyder, David S.; Sweet, Kendra L.; Talpaz, Moshe; Thompson, James; Yang, David T.; Gregory, Kristina M.; Sundar, Hema.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 16, No. 9, 01.09.2018, p. 1108-1135.

Research output: Contribution to journalReview article

Radich, JP, Deininger, M, Abboud, CN, Altman, JK, Berman, E, Bhatia, R, Bhatnagar, B, Curtin, P, DeAngelo, DJ, Gotlib, J, Hobbs, G, Jagasia, M, Kantarjian, HM, Maness-Harris, LJ, Metheny, L, Moore, JO, Pallera, A, Pancari, P, Patnaik, M, Purev, E, Rose, MG, Shah, NP, Smith, BD, Snyder, DS, Sweet, KL, Talpaz, M, Thompson, J, Yang, DT, Gregory, KM & Sundar, H 2018, 'Chronic myeloid leukemia, version 1.2019', JNCCN Journal of the National Comprehensive Cancer Network, vol. 16, no. 9, pp. 1108-1135. https://doi.org/10.6004/jnccn.2018.0071
Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R et al. Chronic myeloid leukemia, version 1.2019. JNCCN Journal of the National Comprehensive Cancer Network. 2018 Sep 1;16(9):1108-1135. https://doi.org/10.6004/jnccn.2018.0071
Radich, Jerald P. ; Deininger, Michael ; Abboud, Camille N. ; Altman, Jessica K. ; Berman, Ellin ; Bhatia, Ravi ; Bhatnagar, Bhavana ; Curtin, Peter ; DeAngelo, Daniel J. ; Gotlib, Jason ; Hobbs, Gabriela ; Jagasia, Madan ; Kantarjian, Hagop M. ; Maness-Harris, Lori J ; Metheny, Leland ; Moore, Joseph O. ; Pallera, Arnel ; Pancari, Philip ; Patnaik, Mrinal ; Purev, Enkhtsetseg ; Rose, Michal G. ; Shah, Neil P. ; Smith, B. Douglas ; Snyder, David S. ; Sweet, Kendra L. ; Talpaz, Moshe ; Thompson, James ; Yang, David T. ; Gregory, Kristina M. ; Sundar, Hema. / Chronic myeloid leukemia, version 1.2019. In: JNCCN Journal of the National Comprehensive Cancer Network. 2018 ; Vol. 16, No. 9. pp. 1108-1135.
@article{753d3084671b4423b07f382e01593cea,
title = "Chronic myeloid leukemia, version 1.2019",
abstract = "Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor (TKI) therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML (CP-CML). The selection TKI therapy should be based on the risk score, toxicity profile of TKI, patient’s age, ability to tolerate therapy, and the presence of comorbid conditions. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CP-CML.",
author = "Radich, {Jerald P.} and Michael Deininger and Abboud, {Camille N.} and Altman, {Jessica K.} and Ellin Berman and Ravi Bhatia and Bhavana Bhatnagar and Peter Curtin and DeAngelo, {Daniel J.} and Jason Gotlib and Gabriela Hobbs and Madan Jagasia and Kantarjian, {Hagop M.} and Maness-Harris, {Lori J} and Leland Metheny and Moore, {Joseph O.} and Arnel Pallera and Philip Pancari and Mrinal Patnaik and Enkhtsetseg Purev and Rose, {Michal G.} and Shah, {Neil P.} and Smith, {B. Douglas} and Snyder, {David S.} and Sweet, {Kendra L.} and Moshe Talpaz and James Thompson and Yang, {David T.} and Gregory, {Kristina M.} and Hema Sundar",
year = "2018",
month = "9",
day = "1",
doi = "10.6004/jnccn.2018.0071",
language = "English (US)",
volume = "16",
pages = "1108--1135",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "9",

}

TY - JOUR

T1 - Chronic myeloid leukemia, version 1.2019

AU - Radich, Jerald P.

AU - Deininger, Michael

AU - Abboud, Camille N.

AU - Altman, Jessica K.

AU - Berman, Ellin

AU - Bhatia, Ravi

AU - Bhatnagar, Bhavana

AU - Curtin, Peter

AU - DeAngelo, Daniel J.

AU - Gotlib, Jason

AU - Hobbs, Gabriela

AU - Jagasia, Madan

AU - Kantarjian, Hagop M.

AU - Maness-Harris, Lori J

AU - Metheny, Leland

AU - Moore, Joseph O.

AU - Pallera, Arnel

AU - Pancari, Philip

AU - Patnaik, Mrinal

AU - Purev, Enkhtsetseg

AU - Rose, Michal G.

AU - Shah, Neil P.

AU - Smith, B. Douglas

AU - Snyder, David S.

AU - Sweet, Kendra L.

AU - Talpaz, Moshe

AU - Thompson, James

AU - Yang, David T.

AU - Gregory, Kristina M.

AU - Sundar, Hema

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor (TKI) therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML (CP-CML). The selection TKI therapy should be based on the risk score, toxicity profile of TKI, patient’s age, ability to tolerate therapy, and the presence of comorbid conditions. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CP-CML.

AB - Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor (TKI) therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML (CP-CML). The selection TKI therapy should be based on the risk score, toxicity profile of TKI, patient’s age, ability to tolerate therapy, and the presence of comorbid conditions. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with CP-CML.

UR - http://www.scopus.com/inward/record.url?scp=85053011304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053011304&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2018.0071

DO - 10.6004/jnccn.2018.0071

M3 - Review article

C2 - 30181422

AN - SCOPUS:85053011304

VL - 16

SP - 1108

EP - 1135

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 9

ER -